Skip to main content
Contact Us
Subscribe
E-Edition
83°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by UroGen Pharma Ltd.
< Previous
1
2
3
Next >
UroGen Pharma to Participate at Upcoming Investor Conferences
May 07, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
New Real-World Retrospective Analysis Presented at AUA 2024 Reports 86% Recurrence-Free Survival (RFS) at 24 Months with JELMYTO® Across All Studied Patient and Disease Characteristics in Cohort of Responders to Induction Therapy
May 05, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Announces Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer at AUA 2024
May 04, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
New Real-World Study on Retrograde Instillation of JELMYTO® for Treatment of Low-Grade Upper Tract Urothelial Cancer Reports Similar Complete Response Rate and Lower Stricture Rate Compared to OLYMPUS Pivotal Trial
May 04, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma to Report 2024 First Quarter Financial Results on Monday, May 13, 2024
May 03, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Announces New Data Presentations at the American Urological Association 2024 Annual Meeting Highlighting Clinical Benefits of Our Portfolio for Urothelial Cancers
April 17, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Announces FDA Acceptance of Investigational New Drug Application for UGN-103, a Next Generation Mitomycin-Based Formulation for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
April 15, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma Files Patent Infringement Action Against Teva Pharmaceuticals
April 03, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma Delivers Double Digit JELMYTO® Growth and Prepares for the Next Phase of the Company with on Track Rolling Submission of UGN-102
March 14, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 08, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma to Report Fourth Quarter and Full-Year 2023 Financial Results on Thursday, March 14, 2024
March 04, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma to Present at TD Cowen 44th Annual Health Care Conference
February 26, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma to Participate at Upcoming Investor Conferences
February 01, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Initiates Submission of a Rolling NDA to the FDA for UGN-102
January 24, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Secures Exclusive License from medac GmbH to Develop a Next-Generation Novel Mitomycin-Based Formulation for Urothelial Cancers
January 17, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma to Participate in the B. Riley Healthcare Conference
January 11, 2024
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 08, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma Reports Third Quarter 2023 Financial Results
November 14, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen will Present Scientific Advances in Bladder Cancer at the Annual Meeting of the Society of Urologic Oncology
November 13, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma to Report Third Quarter 2023 Financial Results on Tuesday, November 14, 2023
November 07, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
Following Pre-NDA Meeting with the FDA, UroGen Announces Rolling NDA Submission for UGN-102 to Begin January 2024
October 03, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 08, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma to Present at Upcoming Investor Conferences
August 31, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma Reports Record JELMYTO Quarterly Sales and Recent Corporate Developments
August 10, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
The Journal of Urology Publishes Peer-Reviewed Article Highlighting UGN-102 Data in Non-Surgical Treatment for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer
August 08, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023
August 02, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 31, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Announces $120 Million Private Placement of Ordinary Shares
July 27, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UGN-102, in Development as the Potential First Non-Surgical Therapy for LG-IR-NMIBC, Met Primary Endpoints in Both Phase 3 ATLAS and ENVISION Clinical Trials
July 27, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
UroGen Pharma Announces the Appointment of James Robinson to its Board of Directors
July 25, 2023
From
UroGen Pharma Ltd.
Via
Business Wire
Tickers
URGN
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.